| Issue |
Med Sci (Paris)
Volume 31, Number 12, Décembre 2015
|
|
|---|---|---|
| Page(s) | 1137 - 1139 | |
| Section | Forum | |
| DOI | https://doi.org/10.1051/medsci/20153112018 | |
| Published online | 16 December 2015 | |
Dépistage du cancer : les promesses illusoires de Pathway Genomics
Chroniques génomiques
Cancer screening: unsupported promises from Pathway Genomics
1
UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS, Espace éthique méditerranéen, hospital d’adultes la Timone, 264, rue Saint-Pierre, 13385
Marseille Cedex 05, France
2
CoReBio PACA, case 901, parc scientifique de Luminy, 13288
Marseille Cedex 09, France
*
bertrand.jordan@univ-amu.fr
**
brjordan@orange.fr
Abstract
The “liquid biopsy” approach shows promise for characterization and monitoring of cancer during treatment; however a blood-based detection test for “high-risk” but asymptomatic individuals, recently introduced by Pathway Genomics, lacks supporting data and has no proven clinical utility.
© 2015 médecine/sciences – Inserm
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.